CY1111259T1 - Απο του στοματος εντερικη στερεα μορφη δοσολογιας ενος δισφωσφονικου που περιεχει παραγοντα χηλικης συμπλεξης - Google Patents

Απο του στοματος εντερικη στερεα μορφη δοσολογιας ενος δισφωσφονικου που περιεχει παραγοντα χηλικης συμπλεξης

Info

Publication number
CY1111259T1
CY1111259T1 CY20101100978T CY101100978T CY1111259T1 CY 1111259 T1 CY1111259 T1 CY 1111259T1 CY 20101100978 T CY20101100978 T CY 20101100978T CY 101100978 T CY101100978 T CY 101100978T CY 1111259 T1 CY1111259 T1 CY 1111259T1
Authority
CY
Cyprus
Prior art keywords
bisphosphonate
dosage form
chelating agent
bissofonic
solid dosage
Prior art date
Application number
CY20101100978T
Other languages
English (en)
Inventor
Richard John Dansereau
David Ernest Burgio Jr
Original Assignee
Warner Chilcott Company, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35355642&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1111259(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Chilcott Company, Llc filed Critical Warner Chilcott Company, Llc
Publication of CY1111259T1 publication Critical patent/CY1111259T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/22—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of calcitonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

Από του στόματος μορφές δοσολογίας ενός δισφωσφονικού που αποτελείται από ασφαλή και αποτελεσματική ποσότητα μιας φαρμακευτικής σύνθεσης που περιλαμβάνει ένα δισφωσφονικό, έναν παράγοντα χηλικής σύμπλεξης και μέσα για πραγματοποίηση επιβραδυνόμενης απελευθέρωσης του δισφωσφονικού και του παράγοντα χηλικής σύμπλεξης στην κατώτερη γαστρεντερική οδό, παρέχει απελευθέρωση της φαρμακευτικής σύνθεσης στην κατώτερη γαστρεντερική οδό του υποκειμένου θηλαστικού και φαρμακευτικώς αποτελεσματική απορρόφηση του δισφωσφονικού με ή χωρίς τροφή ή ποτά. Η παρούσα εφεύρεση σημαντικά ανακουφίζει την αλληλεπίδραση μεταξύ δισφωσφονικών και τροφής ή ποτών, η οποία αλληλεπίδραση έχει σαν αποτέλεσμα το δραστικό συστατικό δισφωσφονικό να μην είναι διαθέσιμο για απορρόφηση. Η προκύπτουσα από του στόματος μορφή δοσολογίας μπορεί έτσι να ληφθεί με τροφή ή χωρίς τροφή. Περαιτέρω, η παρούσα εφεύρεση πραγματοποιεί απελευθέρωση του δισφωσφονικού και του παράγοντα χηλικής σύμπλεξης στην κατώτερη GI οδό, ανακουφίζοντας σημαντικά τον ερεθισμό της ανώτερης GI που συνδυάζεται με θεραπείες δισφωσφονικού. Αυτά τα ευεργετήματα απλοποιούν προηγούμενες πολύπλοκες αγωγές θεραπείας και μπορεί να οδηγήσουν σε αυξημένη αποδοχή από τον ασθενή με θεραπείες δισφωσφονικού.
CY20101100978T 2004-05-24 2010-10-27 Απο του στοματος εντερικη στερεα μορφη δοσολογιας ενος δισφωσφονικου που περιεχει παραγοντα χηλικης συμπλεξης CY1111259T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57388104P 2004-05-24 2004-05-24
EP05735411A EP1753395B1 (en) 2004-05-24 2005-04-14 Enteric solid oral dosage form of a bisphosphonate containing a chelating agent

Publications (1)

Publication Number Publication Date
CY1111259T1 true CY1111259T1 (el) 2015-08-05

Family

ID=35355642

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20101100978T CY1111259T1 (el) 2004-05-24 2010-10-27 Απο του στοματος εντερικη στερεα μορφη δοσολογιας ενος δισφωσφονικου που περιεχει παραγοντα χηλικης συμπλεξης
CY20221100478T CY1125501T1 (el) 2004-05-24 2022-07-12 Εντερικη στερεη απο του στοματος χορηγουμενη δοσολογικη μορφη ενος διφωσφονικου αλατος που περιεχει εναν χηλικο παραγοντα

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20221100478T CY1125501T1 (el) 2004-05-24 2022-07-12 Εντερικη στερεη απο του στοματος χορηγουμενη δοσολογικη μορφη ενος διφωσφονικου αλατος που περιεχει εναν χηλικο παραγοντα

Country Status (32)

Country Link
EP (3) EP2283825B1 (el)
JP (2) JP4605221B2 (el)
KR (5) KR20130063041A (el)
CN (2) CN1956706A (el)
AR (2) AR049022A1 (el)
AT (1) ATE475412T1 (el)
AU (2) AU2005247299B2 (el)
BR (1) BRPI0511530A (el)
CA (1) CA2566798A1 (el)
CY (2) CY1111259T1 (el)
DE (1) DE602005022578D1 (el)
DK (2) DK2283825T3 (el)
ES (3) ES2921364T3 (el)
HK (1) HK1161130A1 (el)
HR (1) HRP20100583T1 (el)
HU (1) HUE059143T2 (el)
IL (1) IL179090A (el)
MA (1) MA28657B1 (el)
MX (1) MXPA06013575A (el)
MY (1) MY144704A (el)
NO (1) NO20065969L (el)
NZ (2) NZ587774A (el)
PE (1) PE20060256A1 (el)
PL (2) PL2283825T3 (el)
PT (3) PT2269584T (el)
RS (1) RS51562B (el)
RU (1) RU2359678C2 (el)
SI (1) SI1753395T1 (el)
SM (1) SMAP200600038A (el)
TW (2) TWI351285B (el)
WO (1) WO2005115331A2 (el)
ZA (1) ZA200609446B (el)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
US7645459B2 (en) * 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of bisphosphonates
AU2011218625B2 (en) * 2004-05-24 2014-03-20 Theramex HQ UK Limited Dosage forms of risedronate
KR20070121759A (ko) 2005-03-17 2007-12-27 엘란 파마 인터내셔널 리미티드 나노입자형 비스포스포네이트 조성물
EP1937362B1 (en) * 2005-09-16 2013-03-27 Selamine Ltd. Bisphosphonate formulation
US7473684B2 (en) 2005-09-16 2009-01-06 Selamine Limited Bisphosphonate formulation
US7704977B2 (en) 2006-04-07 2010-04-27 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
CN101530415A (zh) * 2008-03-10 2009-09-16 北京德众万全医药科技有限公司 一种含有双膦酸盐的药物组合物及其制备方法
JP2011519928A (ja) 2008-05-07 2011-07-14 メリオン・リサーチ・Ｉｉｉ・リミテッド ペプチドの組成物及びその調製方法
WO2010014766A1 (en) * 2008-07-31 2010-02-04 Warner Chilcott Company, Llc Low dosage forms of risedronate or its salts
AU2010278860B2 (en) 2009-07-31 2016-05-26 Thar Pharma, Llc Crystallization method and bioavailability
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
FR2954320B1 (fr) 2009-12-17 2012-06-15 Cll Pharma Composition pharmaceutique orale suprabiodisponible contenant un acide biphosphonique ou un de ses sels
JP5380553B2 (ja) * 2010-02-10 2014-01-08 富士フイルムＲｉファーマ株式会社 放射性金属標識抗カドヘリン抗体
US9089484B2 (en) 2010-03-26 2015-07-28 Merrion Research Iii Limited Pharmaceutical compositions of selective factor Xa inhibitors for oral administration
PT2554168T (pt) 2010-03-29 2018-02-28 Astellas Pharma Inc Composição farmacêutica de libertação controlada
US9340565B2 (en) 2010-11-24 2016-05-17 Thar Pharmaceuticals, Inc. Crystalline forms
AU2012204213A1 (en) 2011-01-07 2013-06-13 Merrion Research Iii Limited Pharmaceutical compositions of iron for oral administration
CN102885759A (zh) * 2011-07-20 2013-01-23 杭州赛利药物研究所有限公司 利塞膦酸钠延释制剂及其制备方法
KR101324425B1 (ko) * 2011-07-22 2013-11-01 동아에스티 주식회사 증가된 비스포스포네이트의 생체이용률을 가지는 경구투여 약제
WO2013015599A2 (en) * 2011-07-28 2013-01-31 Yuhan Corporation Pharmaceutical composition for oral administration comprising bisphosphonic acid or its salt
EP2572736A1 (en) * 2011-09-23 2013-03-27 Spago Imaging AB Nanostructures comprising manganese
US9827192B2 (en) 2012-05-14 2017-11-28 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9782421B1 (en) 2012-05-14 2017-10-10 Antecip Bioventures Ii Llc Neridronic acid molecular complex for treating complex regional pain syndrome
US9949993B2 (en) 2012-05-14 2018-04-24 Antecip Bioventures Ii Llc Compositions for administration of zoledronic acid or related compounds for treating low back pain
US10092581B2 (en) 2014-05-15 2018-10-09 Antecip Bioventures Ii Llc Osteoclast inhibitors such as zoledronic acid for low back pain treatment
US10111837B2 (en) 2012-05-14 2018-10-30 Antecip Bioventures Ii Llc Dosage forms for oral administration of zoledronic acid or related compounds
US10493085B2 (en) 2012-05-14 2019-12-03 Antecip Bioventures Ii Llc Neridronic acid and other bisphosphonates for treating complex regional pain syndrome and other diseases
US9211257B2 (en) 2012-05-14 2015-12-15 Antecip Bioventures Ii Llc Osteoclast inhibitors for knee conditions
US10034890B2 (en) 2012-05-14 2018-07-31 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9770457B2 (en) 2012-05-14 2017-09-26 Antecip Bioventures Ii Llc Neridronic acid for treating bone marrow lesion
US10028908B2 (en) 2012-05-14 2018-07-24 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9956237B2 (en) 2012-05-14 2018-05-01 Antecip Bioventures Ii Llc Osteoclast inhibitors for knee conditions
US10413561B2 (en) 2012-05-14 2019-09-17 Antecip Bioventures Ii Llc Neridronic acid and other bisphosphonates for treating complex regional pain syndrome and other diseases
US9901589B2 (en) 2012-05-14 2018-02-27 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9999628B2 (en) 2012-05-14 2018-06-19 Antecip Bioventures Ii Llc Neridronic acid for treating complex regional pain syndrome
US9861648B2 (en) 2012-05-14 2018-01-09 Antecip Boiventures Ii Llc Osteoclast inhibitors for knee conditions
US9999629B2 (en) 2012-05-14 2018-06-19 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9789128B2 (en) 2012-05-14 2017-10-17 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US10016446B2 (en) 2012-05-14 2018-07-10 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating Paget's disease of bone
US9844559B2 (en) 2012-05-14 2017-12-19 Antecip Bioventures Ii Llc Neridronic acid for treating bone marrow lesions
US10413560B2 (en) 2012-05-14 2019-09-17 Antecip Bioventures Ii Llc Dosage forms for oral administration of zoledronic acid or related compounds for treating disease
US10463682B2 (en) 2012-05-14 2019-11-05 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating low back pain
US11654152B2 (en) 2012-05-14 2023-05-23 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating disease
US10350227B2 (en) 2012-05-14 2019-07-16 Antecip Bioventures Ii Llc Neridronic acid for treating complex regional pain syndrome
US9895383B2 (en) 2012-05-14 2018-02-20 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US10039773B2 (en) 2012-05-14 2018-08-07 Antecip Bioventures Ii Llc Neridronic acid for treating arthritis
DK2849758T3 (en) * 2012-05-14 2018-05-14 Antecip Bioventures Ii Llc COMPOSITIONS INCLUDING ZOLEDRONIC ACID OR RELATED COMPOUNDS TO RELIEVE INFLAMMATORY Pain and RELATED CONDITIONS
US9956234B2 (en) 2012-05-14 2018-05-01 Antecip Bioventures Ii Llc Osteoclast inhibitors for joint conditions
US9820999B2 (en) 2012-05-14 2017-11-21 Antecip Bioventures Ii Llc Neridronic acid for treating complex regional pain syndrome
US9877977B2 (en) 2012-05-14 2018-01-30 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US10004756B2 (en) 2014-05-15 2018-06-26 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9707247B2 (en) 2012-05-14 2017-07-18 Antecip Bioventures Ii Llc Compositions for administration of zoledronic acid or related compounds for treating low back pain
US9925203B2 (en) 2012-05-14 2018-03-27 Antecip Bioventures Ii Llc Compositions for administration of zoledronic acid or related compounds for treating low back pain
US10016445B2 (en) 2012-05-14 2018-07-10 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9827256B2 (en) 2014-05-27 2017-11-28 Antecip Bioventures Ii Llc Compositions for administration of zoledronic acid or related compounds for treating lower back pain
US9943531B2 (en) 2014-08-08 2018-04-17 Antecip Bioventures Ii Llc Osteoclast inhibitors such as zoledronic acid for low back pain treatment
US9867840B2 (en) 2014-05-27 2018-01-16 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US10080765B2 (en) 2012-05-14 2018-09-25 Antecip Bioventures Ii Llc Neridronic acid for treating complex regional pain syndrome
US10173986B2 (en) 2012-05-14 2019-01-08 Antecip Bioventures Ii Llc Methods for the safe administration of imidazole or imidazolium compounds
US9717747B2 (en) 2012-05-14 2017-08-01 Antecip Bioventures Ii Llc Osteoclast inhibitors for knee conditions
US9867839B2 (en) 2012-05-14 2018-01-16 Antecip Bioventures Ii Llc Osteoclast inhibitors for joint conditions
US9795622B2 (en) 2012-05-14 2017-10-24 Antecip Bioventures Ii Llc Neridronic acid for treating pain associated with a joint
US10028969B2 (en) 2012-05-14 2018-07-24 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9956238B2 (en) 2014-05-15 2018-05-01 Antecip Bioventures Ii Llc Compositions for administration of zoledronic acid or related compounds for treating low back pain
CN103784405B (zh) * 2012-11-02 2015-07-08 沈阳药科大学 一种改善利塞膦酸钠口服生物利用度的制剂及其制备方法
EP3250191B1 (en) 2015-01-29 2024-01-17 Novo Nordisk A/S Tablets comprising glp-1 agonist and enteric coating
RU2609871C1 (ru) * 2015-08-10 2017-02-06 Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ГНЦ ВБ "Вектор" Роспотребнадзора) Противоопухолевое средство
US10195218B2 (en) 2016-05-31 2019-02-05 Grunenthal Gmbh Crystallization method and bioavailability
CN109200020A (zh) * 2017-07-07 2019-01-15 长春海悦药业股份有限公司 一种埃索美拉唑镁的药物组合物
WO2023249087A1 (ja) * 2022-06-24 2023-12-28 三生医薬株式会社 医薬組成物およびその製造方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA777769A (en) 1963-03-18 1968-02-06 H. Roy Clarence Substituted methylene diphosphonic acid compounds and detergent compositions
IT1201087B (it) 1982-04-15 1989-01-27 Gentili Ist Spa Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche
FR2531088B1 (fr) 1982-07-29 1987-08-28 Sanofi Sa Produits anti-inflammatoires derives de l'acide methylenediphosphonique et leur procede de preparation
US4639338A (en) 1984-08-06 1987-01-27 Ciba-Geigy Corporation Preparation of crystalline disodium 3-amino-1-hydroxypropane-1,1-diphosphonate pentahydrate
US4812311A (en) 1984-12-21 1989-03-14 The Procter & Gamble Company Kit for use in the treatment of osteoporosis
IL77243A (en) 1984-12-21 1996-11-14 Procter & Gamble Pharmaceutical compositions containing geminal diphosphonic acid compounds and certain such novel compounds
US4761406A (en) 1985-06-06 1988-08-02 The Procter & Gamble Company Regimen for treating osteoporosis
DE3623397A1 (de) 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
CA1339805C (en) 1988-01-20 1998-04-07 Yasuo Isomura (cycloalkylamino)methylenebis(phosphonic acid) and medicines containing the same as an active
US4922007A (en) 1989-06-09 1990-05-01 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof
US5019651A (en) 1990-06-20 1991-05-28 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (ABP) or salts thereof
CA2122479C (en) * 1991-11-22 1998-08-25 Richard John Dansereau Risedronate delayed-release compositions
US5431920A (en) * 1993-09-21 1995-07-11 Merck Frosst, Canada, Inc. Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents
US5462932A (en) * 1994-05-17 1995-10-31 Merck & Co., Inc. Oral liquid alendronate formulations
ATE289199T1 (de) 1995-06-06 2005-03-15 Merck & Co Inc Formulierungen mit dem wasserfreien mononatriumsalz von alendronat und deren verwendung zur behandlung von knochenkrankheiten
AU6148396A (en) 1995-06-06 1996-12-24 Merck & Co., Inc. Disodium alendronate formulations
DE69726879T2 (de) * 1996-05-17 2004-10-14 Merck & Co., Inc. Biphosphonat-formulierung mit brausewirkung
SE9703691D0 (sv) * 1997-10-10 1997-10-10 Astra Ab Pharmaceutical compositions
US6290938B1 (en) * 1998-07-30 2001-09-18 The Procter & Gamble Company Sunscreen compositions
US6008207A (en) 1998-08-13 1999-12-28 Merck & Co., Inc. Anhydrous alendronate monosodium salt formulations
CZ2001629A3 (cs) 1998-08-27 2001-08-15 Teva Pharmaceutical Industries Ltd. Nové formy hydrátů alendronátu sodného, způsob jejich výroby a farmaceutické kompozice na jejich bázi
SE9901272D0 (sv) * 1999-04-09 1999-04-09 Astra Ab New improved formulation
AR021347A1 (es) * 1999-10-20 2002-07-17 Cipla Ltd Una composicion farmaceutica que contiene acido(s) bisfosfoncio o sal(es) del mismo y un proceso de preparacion de la misma
WO2001032185A1 (en) * 1999-11-02 2001-05-10 Cipla Ltd. A pharmaceutical composition containing bisphosphonic acid(s) or salt(s) thereof and a process of preparing thereof
US6410520B2 (en) 2000-02-01 2002-06-25 The Procter & Gamble Company Selective crystallization of 3-pyridyl-1-hydroxyethylidene-1, 1-bisphosphonic acid sodium as the hemipentahydrate or monohydrate
CA2415643C (en) * 2000-07-17 2010-11-16 Yamanouchi Pharmaceutical Co., Ltd. Pharmaceutical composition for oral use with improved absorption
CA2469779C (en) * 2001-12-21 2008-02-12 The Procter & Gamble Company Method for the treatment of bone disorders
BR0106601A (pt) 2001-12-21 2003-09-09 Libbs Farmaceutica Ltda Composição farmacêutica contendo bisfosfonato para o tratamento de doenças relacionadas ao metabolismo de cálcio e/ou fosfato, seu uso na preparação de medicamento para o tratamento de doenças relacionadas ao metabolismo de cálcio e/ou fosfato, método de tratamento de doenças relacionadas ao metabolismo de cálcio e/ou fosfato

Also Published As

Publication number Publication date
CN102225047B (zh) 2013-09-18
MXPA06013575A (es) 2007-02-08
WO2005115331A2 (en) 2005-12-08
NO20065969L (no) 2007-02-23
AR098686A2 (es) 2016-06-08
AU2008202652A1 (en) 2008-07-10
PE20060256A1 (es) 2006-05-04
ZA200609446B (en) 2007-11-28
RU2006140888A (ru) 2008-06-27
IL179090A (en) 2017-03-30
PT1753395E (pt) 2010-10-21
DE602005022578D1 (de) 2010-09-09
AU2005247299A1 (en) 2005-12-08
ES2349584T3 (es) 2011-01-05
RS51562B (en) 2011-08-31
KR20110018465A (ko) 2011-02-23
HUE059143T2 (hu) 2022-10-28
KR20130063041A (ko) 2013-06-13
NZ587774A (en) 2012-03-30
PL1753395T3 (pl) 2011-01-31
BRPI0511530A (pt) 2008-01-02
HRP20100583T1 (hr) 2010-12-31
SMP200600038B (it) 2006-12-27
CN102225047A (zh) 2011-10-26
EP2283825A1 (en) 2011-02-16
CY1125501T1 (el) 2024-02-16
EP2283825B1 (en) 2022-04-13
KR20070015596A (ko) 2007-02-05
IL179090A0 (en) 2007-03-08
AU2008202652B2 (en) 2010-02-11
KR101411117B1 (ko) 2014-06-25
SI1753395T1 (sl) 2011-01-31
ATE475412T1 (de) 2010-08-15
PT2283825T (pt) 2022-06-30
KR20080083068A (ko) 2008-09-12
JP2008500339A (ja) 2008-01-10
ES2921141T3 (es) 2022-08-18
MY144704A (en) 2011-10-31
PT2269584T (pt) 2022-07-01
HK1161130A1 (en) 2012-08-24
SMAP200600038A (it) 2006-12-27
KR101388777B1 (ko) 2014-04-23
TW200607514A (en) 2006-03-01
DK1753395T3 (da) 2010-11-08
EP2269584B1 (en) 2022-04-13
JP2010275319A (ja) 2010-12-09
EP1753395B1 (en) 2010-07-28
KR20120104446A (ko) 2012-09-20
CA2566798A1 (en) 2005-12-08
CN1956706A (zh) 2007-05-02
TW201138783A (en) 2011-11-16
AU2005247299B2 (en) 2008-05-15
AR049022A1 (es) 2006-06-21
PL2283825T3 (pl) 2022-08-16
JP4605221B2 (ja) 2011-01-05
EP2269584A1 (en) 2011-01-05
WO2005115331A3 (en) 2006-01-19
TWI351285B (en) 2011-11-01
NZ551118A (en) 2010-09-30
DK2283825T3 (da) 2022-06-27
EP1753395A2 (en) 2007-02-21
ES2921364T3 (es) 2022-08-24
RU2359678C2 (ru) 2009-06-27
MA28657B1 (fr) 2007-06-01

Similar Documents

Publication Publication Date Title
CY1111259T1 (el) Απο του στοματος εντερικη στερεα μορφη δοσολογιας ενος δισφωσφονικου που περιεχει παραγοντα χηλικης συμπλεξης
IN2012DN00827A (el)
CY1119498T1 (el) Συντηγμενα πολυπεπτιδια λεπτινης-abd με ενισχυμενη διαρκεια δρασης
TW200630093A (en) Dose forms
AR050418A1 (es) Dosificacion fija de anticuerpos her
CY1111478T1 (el) Ενδειξη δοσολογιας προγεστερονης στην αντιμετωπιση τραυματικης εγκεφαλικης βλαβης
MX2016008362A (es) Combinaciones farmaceuticas.
CY1111065T1 (el) Φαρμακευτικη συνθεση που περιεχει μια ωμεγα-καρβοξυαρυλ υποκατεστημενη διφαινυλ ουρια για τη θεραπευτικη αντιμετωπιση του καρκινου
CY1112473T1 (el) Μεθοδοι θεραπειας για καρκινους σχετιζομενους με β κυτταρα
MX2009012598A (es) Formas de dosis que comprenden vx-950 y su regimen de dosificacion.
JP2009539994A5 (el)
MX2015009546A (es) Dosificacion aumentada de efavirenz para el tratamiento de cancer.
JP2011500589A5 (el)
JP2018506533A5 (el)
MX2021004120A (es) Regimen de dosificacion para antagonistas de tfpi.
MX2021013248A (es) Regimenes de dosificacion para anticuerpos anti-vrs y composiciones que los incluyen.
WO2011006084A3 (en) Vaccines with oncofetal antigen/ilrp-loaded autologous dendritic cells and uses thereof
Scambia et al. Combining targeted therapies in ovarian cancer
Garcia-Manero Azacitidine/panobinostat
Shimoyama Gimeracil/oteracil/tegafur
Campos-VarelaMD Ribavirin/simeprevir/sofosbuvir
EA201170414A1 (ru) Способы лечения вазомоторных симптомов у кастрированных пациентов с раком предстательной железы, низкими дозами ципротерона ацетата
Kanzaki Methotrexate/tacrolimus
Cundy First report of hypertrophic osteoarthropathy: case report
Cho Gastrointestinal intolerance and easy bruising: case report